Clover Health Investments (CLOV) Issues Response to Short Seller Hindenburg Research
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
- Wall Street stocks fall as weak GDP growth spreads rate-cut gloom
- Q1 US GDP shows surprise slowing and uncomfortable inflation
- Alphabet (GOOGL) soars 16% on Q1 results beat, first-ever dividend
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil settles higher as weak U.S. economic growth offset by supply concerns
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hasbro (HAS) brand strength sees earnings top expectations
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- After-hours movers: Alphabet, Microsoft, Snap, Intel, and more
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
Clover Health (CLOV) Response to Short Seller 'Compelling' - BofA Securities
February 5, 2021 8:28 AM ESTBofA Securities analyst Kevin Fischbeck reiterated a Buy rating and $20.00 price target on Clover Health (NASDAQ: CLOV), saying the company's response to the short seller was "compelling."
For an analyst ratings summary and ratings history on Clover Health... More
Hindenburg Research Negative on Clover Health (CLOV), Calls Out SPAC King Chamath Palihapitiya
February 4, 2021 8:18 AM EST(Updated - February 4, 2021 8:20 AM EST)
Hindenburg Research issued a negative on Clover Health (NASDAQ: CLOV).
Hindenburg said SPAC King Chamath Palihapitiya misled investors about critical aspects of Clovers business in the run-up to the companys SPAC go-public transaction last... More
